<DOC>
	<DOCNO>NCT01277484</DOCNO>
	<brief_summary>Brief Scientific Rationale : Decitabine show effective treatment MDS associate limited extramedullary toxicity lower dos . Furthermore , hypomethylating effect decitabine require extend period therapy likely beneficial set minimal residual disease transplantation . The drug might exert cytoreductive effect MDS clone , ex vivo expansion strategy use decitabine HDAC inhibitor provide potential expand number hematopoietic stem cell . There lots evidence show drug immunostimulatory effect use enhance graft-versus leukemia effect . And also , investigator suggest decitabine could induce FOXP3 expression , promote conversion naïve T cell Tregs know suppress GVHD maintain GVL effect allo-SCT setting . As , decitabine ideal agent investigate post-transplant setting . The investigator hypothesize post-transplant maintenance therapy decitabine may reduce relapse rate , may maximize beneficial effect reduce TRM ATG-containing FB4 FB2 condition regimen higher-risk MDS AML evolve MDS patient .</brief_summary>
	<brief_title>Dose Finding Study Post-BMT Decitabine Maintenance Treatment Higher-risk MDS MDS/AML</brief_title>
	<detailed_description>1 . Transplant course - BMT HLA-matched sibling suitably match ( 2-allele mismatch ) family unrelated donor perform accord policy institute . - A preparative regimen start 6 day day stem cell infusion 1 . Myeloablative-intensity condition regimen : FB4+ATG 2 . Reduced-intensity condition regimen ; FB2+ATG 3 . Graft-versus-host disease prophylaxis - Sibling transplant : Cyclosporine short-course Methotrexate - Unrelated transplant : Tacrolimus short-course Methotrexate - The dose calcineurin inhibitor ( cyclosporine tacrolimus ) gradually taper day 60 ( sibling transplant ) day 90 ( unrelated transplant ) discontinue within 2 3 month SCT absence graft-versus-host disease . 2 . Decitabine maintenance course - For patient finish transplant procedure meet enrollment criterion , decitabine give dose 5mg/m2/day ~ 15mg/m2/day iv 1 hour 5 consecutive day . The drug repeat every 4 week 12 cycle . - Dose escalation strategy cohort cycle cohort patient base upon quantitatively measure hematological toxicity ( e.g. , ANC platelet count nadir ) . In word , mechanism-based pharmacokinetic / pharmacodynamic model develop use sparsely sample patient ' PK data toxicity response use titrate next cycle dose patient initial dos new cohort patient . In word , mechanism-based pharmacokinetic / pharmacodynamic model develop use sparsely sample patient ' PK data toxicity response use titrate next cycle dose patient initial dos new cohort patient .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria allogeneic transplantation : : Patients diagnosis MDS ( IPSS intermediate2 high ) allogeneic transplantation HLAcompatible unrelated ( HLAA , B , C DRB1 match 2 allele mismatch ) Performance status &lt; ECOG 2 Acceptable organ function define : Serum creatinine &lt; 1.5 time institutional ULN , Serum bilirubin &lt; 1.5 time institutional ULN , AST , ALT alkaline phosphatase &lt; 3 time institutional ULN . Inclusion Criteria decitabine maintenance therapy : 6 10 week alloHSCT patient confirm complete remission ( CR ) within 2 week treatment start ( CR : le 5 % blast aspirate bone marrow sample leukemic blast peripheral blood , cytogenetic aberration ) Performance status &lt; ECOG 2 Acceptable organ function define : Serum creatinine &lt; 1.5 time institutional ULN , Serum bilirubin &lt; 1.5 time institutional ULN , AST , ALT alkaline phosphatase &lt; 3 time institutional ULN . Platelet count ≥ 30,000/μL without platelet transfusion 7 day ANC ≥ 1,000/μL without colony stimulate factor support time enrollment Written inform consent form HIV positive Active uncontrolled infection Pregnancy breastfeeding patient residual disease allo SCT primary graft failure Uncontrolled grade 3 4 acute GVHD patient know suspected hypersensitivity decitabine patient suitable trial accordance principal investigator 's decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>decitabine</keyword>
	<keyword>dose</keyword>
	<keyword>schedule</keyword>
	<keyword>safety</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
</DOC>